A Phase IV Open-label Evaluation of Safety, Tolerability and Patient Acceptance of Atazanavir Boosted With Ritonavir Combined With a Fixed-dose Formulation of Tenofovir DF and Emtricitabine for Non-occupational Prophylaxis Following Potential Exposure to HIV-1
Latest Information Update: 13 Mar 2013
Price :
$35 *
At a glance
- Drugs Atazanavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 24 May 2012 New trial record
- 01 May 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.